Activated Charcoal Alcohol X-Ray Exposed Aluminum
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Activated Charcoal Alcohol X-Ray Exposed Aluminum
- Multi-Ingredient Homeopathic Compound (15 Components): Insufficient Evidence for Repurposing Evaluation
Multi-Ingredient Homeopathic Compound (15 Components): Insufficient Evidence for Repurposing Evaluation
One-Sentence Summary
This submission describes a 15-ingredient compound whose components include activated charcoal, metals (gold, platinum, tin, tellurium), botanical extracts (Phytolacca americana root, Stillingia sylvatica root, Strychnos nux-vomica seed), and homeopathic-classified substances (Causticum, calcium sulfide, nitric acid). The composition pattern is consistent with a homeopathic multi-compound preparation, for which no original approved indication, no DrugBank identifier, and no regulatory license in Taiwan or the United States could be identified. The TxGNN model returned no predicted indications for this entry, and no supporting clinical trials or literature were retrievable for the compound as a whole.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | Not applicable |
| Evidence Level | L5 — model prediction only, but even this is absent |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
This question cannot be answered in the conventional sense, because no repurposing prediction was generated.
The 15-component INN string contains substances characteristic of homeopathic formularies: Causticum (Hahnemann’s potassium-based remedy), Phytolacca americana root (pokeweed), Strychnos nux-vomica seed (nux vomica), elemental metals in homeopathic potency (gold, platinum, tin, tellurium), and an unusual entry labeled “Alcohol, X-Ray Exposed.” These ingredients, as listed, are not individually mapped to a single DrugBank record, and the compound as a whole has no DrugBank ID.
Because the TxGNN knowledge graph requires a valid DrugBank ID and a known indication to anchor its prediction, the model had no entry point for this compound. Without an anchored mechanism of action or a confirmed pharmacological target, the relational scoring that drives TxGNN predictions cannot run.
Safety Considerations
No safety data — warnings, contraindications, or drug interaction records — were retrievable for this compound. Please refer to the individual ingredient package inserts or product-specific documentation for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The compound lacks a DrugBank ID, an approved indication, a confirmed mechanism of action, and any TxGNN-generated repurposing candidate. Without these anchors, neither computational nor evidence-based evaluation can proceed. The multi-ingredient homeopathic composition further complicates standard pharmacological analysis, as individual components act at sub-pharmacological dilutions under homeopathic convention and do not map cleanly to conventional drug–target relationships.
To proceed, the following is needed:
- Identity resolution: Determine whether this compound corresponds to a registered homeopathic product with an NDA or ANDA number (e.g., via FDA’s homeopathic OTC monograph database or HPUS listing). If yes, retrieve the product-level DrugBank or RxNorm ID.
- Indication clarification: Confirm the original intended indication(s) from product labeling or manufacturer documentation.
- MOA documentation: For any ingredients with known pharmacological activity at conventional doses (e.g., activated charcoal for GI adsorption, cysteine as a mucolytic precursor, platinum compounds for cytotoxicity), provide compound-level evidence distinguishing pharmacological from homeopathic use.
- Re-run pipeline: Once a DrugBank ID and indication are confirmed, re-submit to the TxGNN pipeline with corrected metadata.
- Regulatory pathway check: If this is intended as a homeopathic OTC, assess applicability under FDA’s 2019 Homeopathic Drug Products Guidance rather than the standard NDA repurposing pathway.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.